QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) All Versions of this Article: jpet.107.129007v1 323/3/822    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Imbimbo, B. P. Articles by Leon, A. Search for Related Content PubMed PubMed Citation Articles by Imbimbo, B. P. Articles by Leon, A.

NEUROPHARMACOLOGY

1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic Acid (CHF5074), a Novel -Secretase Modulator, Reduces Brain -Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease without Causing Peripheral Toxicity

Research & Development, Chiesi Farmaceutici, Parma, Italy (B.P.I., G.V., F.F., R.V.); Research & Innovation, Padova, Italy (E.D.G., D.C., A.D., M.D.C., A.L.); Department of Neurosciences, Neurology Section, University of Parma, Parma, Italy (V.P., M.F.B.); and Department for Molecular and Developmental Genetics, Vlaams Instituut voor Biotechnologie and Center for Human Genetics, Katholieke Universiteit Leuven, Leuven, Belgium (L.S., B.D.S.)

Received July 20, 2007; accepted September 24, 2007.

	Abstract

Top Abstract Materials and Methods Results Discussion References

 
Some nonsteroidal anti-inflammatory drugs has been shown to allosterically modulate the activity of -secretase, the enzymatic complex responsible for the formation of -amyloid (A). 1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074) is a new -secretase modulator, devoid of anticyclooxygenase (COX) and Notch-interfering activities in vitro. We evaluated the effects of chronic CHF5074 treatment on brain A pathology in Tg2576 transgenic mice. Twenty-eight animals of 9.5 to 10.5 months of age received CHF5074-medicated diet (375 ppm) or standard diet for 17 weeks. Compared with controls, CHF5074 treatment significantly reduced the area occupied by plaques and the number of plaques in cortex (–52.2 ± 5.6%, p = 0.0003 and –48.9 ± 6.6%, p = 0.0004, respectively) and hippocampus (–76.7 ± 6.4%, p = 0.004 and –66.2 ± 10.3%, p = 0.037, respectively). Biochemical analysis confirmed the histopathological measures, with CHF5074-treated animals showing reduced total brain A40 (–49.2 ± 9.2%, p = 0.017) and A42 (–43.5 ± 9.7%, p = 0.027) levels. In a human neuroglioma cell line expressing Swedish mutated form of amyloid precursor protein (H4swe), CHF5074 reduced A42 and A40 secretion, with an IC₅₀ of 3.6 and 18.4 µM, respectively, values consistent with those measured in the brain of the CHF5074-treated Tg2576 mice (6.4 ± 0.4 µM). At 5 µM, no effects were observed on Notch intracellular cleavage in human embryonic kidney 293swe cells. CHF5074 was well tolerated by Tg2576 mice. No abnormal findings were observed upon histopathological examination of the gastrointestinal tract, indicating the absence of COX-related toxicity. Semiquantitative histochemical evaluation of goblet cells in the ileum of vehicle- and CHF5074-treated animals yielded similar results, suggesting no effects on Notch pathway. CHF5074 is therefore a promising therapeutic agent for Alzheimer's disease.

Many epidemiological studies suggest that long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) may delay or prevent the onset of AD (Szekely et al., 2004). Despite this encouraging evidence, all randomized, controlled studies aiming to reduce inflammation in the brain of AD patients produced negative results. The failures include both steroidal anti-inflammatory agents such as prednisone (Aisen et al., 2000) and nonsteroidal anti-inflammatory drugs, e.g., hydroxychloroquine (Van Gool et al., 2001); and nonselective cyclooxygenase (COX) inhibitors, e.g., naproxen (Aisen et al., 2003) and COX-2-selective inhibitors, e.g., rofecoxib (Aisen et al., 2003; Reines et al., 2004) and celecoxib (Sainati et al., 2000). Negative results were also obtained in patients with mild cognitive impairment treated with rofecoxib (Thal et al., 2005) and in normal elderly subjects at risk of developing AD treated with naproxen or celecoxib (ADAPT Research Group et al., 2007). These multiple failures have questioned the role of inflammation in AD.

New insight into understanding the apparent discrepancy between epidemiological studies and clinical trials was the discovery that some NSAIDs decrease the production of A42 (Weggen et al., 2001) and counteract the progression of A pathology in transgenic mouse models of AD (Lim et al., 2000, 2001; Jantzen et al., 2002; Yan et al., 2003; van Groen et al., 2005; Wilcock et al., 2007). The proposed mechanism for this effect is an allosteric modulation of presenilin-1, the main component of the -secretase complex, that is responsible for the formation of A (Eriksen et al., 2003; Takahashi et al., 2003; Weggen et al., 2003b; Beher et al., 2004; Lleó et al., 2004). The inhibition of A42 production is independent from the anti-COX activity, and it depends on the chemical structure of the NSAIDs, with some compounds displaying activity (ibuprofen, sulindac, indomethacin, and flurbiprofen) and others not (naproxen, aspirin, meloxicam, and celecoxib) (Weggen et al., 2001; Morihara et al., 2002; Eriksen et al., 2003). This could explain the negative results of the large AD trials pursued to date, because they were conducted with compounds (naproxen, prednisone, hydroxychloroquine, rofecoxib, and celecoxib) not able to inhibit A secretion in vitro. Interestingly, the only positive study in AD regards indomethacin (Rogers et al., 1993), shown to decrease A42 production in vitro (Weggen et al., 2001) and plaque deposition in vivo (Sung et al., 2004).

The A42-lowering NSAIDs differ from traditional -secretase inhibitors because they do not inhibit the -secretase-mediated cleavages of either APP at the alternative site, or Notch-1 at the S3 site (Weggen et al., 2001, 2003a). Unfortunately, the use of NSAIDs in AD is hampered by gastrointestinal toxicity, which is associated with COX inhibition.

We have synthesized new NSAID derivatives endowed with selective A42-lowering activity but devoid of COX inhibitory activity, thus suitable for chronic use in AD patients (Peretto et al., 2005). Within this new chemical series, CHF5074 (Fig. 1) proved to be of major interest. In human neuroglioma cells (H4swe), CHF5074 preferentially lowers A42 secretion, with an IC₅₀ of 40 µM (Imbimbo et al., 2007). CHF5074 does not display inhibitory activity on COX-1 and COX-2 enzymes when used at concentrations up to 100 and 300 µM, respectively (Imbimbo et al., 2007). At 100 µM, CHF5074 does not alter the expression profile of several Notch intracellular domain-responsive genes (Imbimbo et al., 2007). In rats, CHF5074 is orally well absorbed (50%), and it is slowly eliminated from plasma (t_1/2 = 20.7 h) (Peretto et al., 2005). In young Tg2576 transgenic mice, short-term oral dosing with CHF5074 causes dose-dependent reduction of plasma A42.

View larger version (6K): [in this window] [in a new window]   Fig. 1. Chemical structure of CHF5074.

We performed the present study to determine the effect of chronic treatment with CHF5074 on brain A levels and amyloid plaque deposition in the Tg2576 mouse model of AD. In addition, we histologically examined peripheral tissues for signs of toxicity, in particular those that may be related to COX inhibition or altered Notch signaling.

	Materials and Methods

Top Abstract Materials and Methods Results Discussion References

 
Animals and Treatment. All procedures were conducted in accordance with the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the National Institutes of Health. Tg2576 transgenic mice (male and female) expressing Swedish mutated form of human APP (APPswe) (Hsiao et al., 1996) were bred in-house. All animals were maintained on a 12:12-h light/dark cycle with unrestricted access to food and water until use. Twenty-eight mice of 9.5 to 10.5 months of age were treated with CHF5074 (375 ppm in the diet) or standard diet (controls) for 17 weeks. At week 17, animals were sacrificed by decapitation, and brains were rapidly removed and divided in the two hemispheres. One hemisphere was used for measurements of A plaques, and the other hemisphere was used for extractable A. Blood samples were collected in EDTA-coated tubes and centrifuged at 800g for 20 min to separate plasma. Plasma samples were divided into two aliquots of approximately 100 µl each, and they were stored at –80°C until A or CHF5074 assay. Peripheral tissues, i.e., liver, kidneys, spleen, esophagus, stomach, duodenum, jejunum, ileum, cecum, colon, and rectum, were collected for histological evaluations.

Brain A Extraction. A40 and A42 were extracted from brain by using both the SDS and formic acid (FA) methods. Because -secretase modulators are thought to affect mainly SDS-extractable A pools, i.e., the newly formed A (Yan et al., 2003; Dvir et al., 2006), a double SDS extraction was performed in an attempt to maximize SDS-extractable A. One hemisphere was first homogenated in 2% SDS in water [100 mg/ml (wet w/v)] containing protease inhibitors (Complete Protease Inhibitor Cocktail; Roche Diagnostics, Basel, Switzerland) and an aliquot of 500 µl was centrifuged at 16,000g for 10 min. Supernatants were collected (first SDS aliquot) and stored at –80°C. The pellet was resuspended in 2% SDS containing protease inhibitors and centrifuged at 100,000g for 1 h at 4°C. The supernatant was collected (second SDS aliquot) and stored at –80°C. Pellets obtained after the second SDS extraction were mixed with 500 µl of 70% FA and centrifuged at 100,000g at 4°C for 1 h. Supernatants were collected and stored at –80°C for assessment of A levels.

A Measurements in Brain Extracts and Plasma. Levels of A40 and A42 in plasma and in brain extracts were measured with commercial ELISA kits (The Genetics Company, Zurich, Switzerland). The microtiter plates were coated with capturing purified monoclonal antibodies specifically recognizing the C terminus of human A40 (clone G2-10, reactive to amino acid residues 31–40, isotype IgG2b, ) or A42 (clone G2-13, reactive to amino acid residues 33–42, isotype IgG1, ). As detection antibody, a monoclonal biotin-conjugated antibody recognizing the N terminus of human A (clone W0-2, reactive to amino acid residues 4–10, isotype IgG2a, ) was used. The assay was linear in the range 25 to 500 pg/ml, and the detection limit was 25 pg/ml. Before A40 and A42 ELISA determinations, the two brain SDS aliquots (50 µl each) were pooled and diluted 1:800 and 1:200 in standard diluent for A40 and A42 assay, respectively (SDS-extracted A). Supernatants obtained following extraction with FA were neutralized with 20 vol of 1 M Tris, pH 11.0 (FA-extracted A). Total A40 and A42 levels were the sum of the double SDS- and FA-extracted fractions. Plasma was diluted 1:4 for A42 and 1:20 for A40 determinations.

Immunohistochemistry. For A plaque measurements, brain hemispheres were fixed by immersion in Alcolin (DiaPath, Martinengo, Italy) for 2 weeks. The hemibrains were then cut coronally into two blocks, and then tissue was dehydrated and embedded in paraffin. A series of coronal sections at the levels of anterior striatum, anterior hippocampus, and middle hippocampus were cut at 10 µm in thickness. Before immunohistochemistry for A, the slides were immersed in 10% buffered formalin overnight. Sections were subsequently incubated in 80% FA for 15 min to expose the epitope. Staining of A plaques was performed by immunohistochemistry using 1:500-diluted 6E10 antibodies (Signet Laboratories, Dedham, MA), as primary antibody, and biotin-conjugated mouse-on-mouse kit Peroxidase (Dako Denmark A/S, Glostrup, Denmark), as revealing system. Peroxidase activity was detected by treatment with 3,3'-diaminobenzidine (Hoffman-La Roche, Nutley, NJ). Slides were photographed using a digital Nikon DS microscope color camera. Digital images were analyzed using NIS-Elements software (Nikon, Tokyo, Japan). Each image was analyzed using the automated target detection mode. Images size was 1280 x 960 pixels and target area had a size of 68,000 µm². The software determined numbers of plaques, mean areas of plaques, and plaque area fraction (immunopositive area/total area used as scan object). We performed nine counts for each of the three above-mentioned levels. Analyses were performed only in the cortex and hippocampus using 10x objective. Glial filaments in CA1 region of hippocampus were stained with specific glial fibrillar acidic protein (GFAP) antibodies (Z0334; Dako Denmark A/S), using 1:800 dilution. For the counts in this region, we used a 20x objective and a target area of 17,300 µm².

Histological Examinations. Tissue samples of liver, kidneys, spleen, esophagus, stomach, duodenum, jejunum, ileum, cecum, colon, and rectum, fixed in 10% buffered formalin, were trimmed, dehydrated, embedded in paraffin wax, and sectioned at 5 µmin thickness. Slides were stained with hematoxylin and eosin, and they were examined by a blinded skilled pathologist for the qualitative evaluation of any treatment-related changes. Samples of ileum from all animals were sectioned at 5 µm in thickness and stained with Alcian Blue to reveal mucopolysaccharides and glycosaminoglycans in the goblet cells. Staining was rated according the following ordinal scale: 0, no specific positive reaction detected; 1, few scattered cells reacting weakly positive; 2, many weakly positive cells; 3, many strongly positive cells; and 4, extremely strong positive cells.

Pharmacokinetics. CHF5074 levels in plasma and in brain samples were measured by liquid chromatography as described previously (Imbimbo et al., 2007). In brief, samples were prepared by adding 300 µl of acetonitrile and 40 µl of 40% phosphoric acid to 100 µl of plasma or brain homogenate and by placing the mixture in a vortex for 5 s. Plasma and brain samples were then centrifuged at 14,000 rpm for 5 min, and the supernatants (15 and 50 µl, respectively) were injected into the high-performance liquid chromatography system. Equipment systems with fluorescence (Waters 474; Waters, Guyancourt, France) or mass spectrometry (API 2000; Applied Biosystems, Foster City, CA) detectors were used. The chromatographic conditions were adapted to each compound to obtain good peak separation and detection sensitivity. A mixture of 20 mM ammonium formate buffer/acetonitrile/methanol was used as mobile phase for the fluorescence detector. The assay was linear between 400 and 20,000 ng/g in brain and between 100 and 8500 ng/ml in plasma, with limits of quantitation of 400 ng/g in brain and 100 ng/ml in plasma.

Studies in H4swe and HEK293swe Cells. A42 and A40 were measured in the culture medium of H4swe human neuroglioma cells and of HEK293swe human embryonic kidney 293 cells, both expressing APPswe, as reported previously (Camacho et al., 2004; Facchinetti et al., 2006). In brief, cells were seeded onto 24-well plates (2 x 10⁵ cell/well) in culture medium (Opti-MEM; Invitrogen, Carlsbad, CA) containing 10% fetal bovine serum, and the cells were allowed to grow to confluence for 24 h, in 5% CO₂, 95% air in a humidified atmosphere. Cells were exposed overnight to increasing concentrations of CHF5074 (0.03–100 µM) and/or (R)-flurbiprofen (10–300 µM) in culture medium (Opti-MEM) without serum. Both compounds were dissolved in dimethyl sulfoxide (0.1% final concentration). At the end of the treatment, A40 and A42 in culture media were measured by ELISA. Cell viability was assessed with the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide assay. For Notch assays, HEK cells were seeded in six-well plates and cultured at 37°C in the presence of 5% CO₂. After 24 h of incubation, cultures (60% confluence) were transfected using FuGENE-6 (Roche Diagnostics) with 1 µg of pCS2NotchE plasmid. After 48 h, medium was discarded, and a minimum volume of Dulbecco's modified Eagle's medium (Invitrogen) supplemented with increasing concentrations of CHF5074 (5–200 µM) was added to the cells for 16 h. After this period, 10 µM lactacystin was added to the cells to block degradation of Notch intracellular domain. Cells were lysed in 1% Triton X-100, and postnuclear fractions were isolated by centrifugation at 10,000g at 4°C for 15 min. Protein concentrations were determined by the Bradford assay (Pierce Chemical, Rockford, IL). Proteins were resolved in 10% Bis-Tris SDS-polyacrylamide gel electrophoresis gels (Invitrogen), and then they were transferred to nitrocellulose membranes for Western blot detection with anti-myc monoclonal antibody 9E10 (Sanver Tech, Heerhugowaard, The Netherlands), Anti-cleaved Notch (val 1744; Westburg, Leusden, The Netherlands), and anti--actin (Sigma-Aldrich, St. Louis, MO). Signals were detected using Odyssey IR detection (LI-COR Biosciences, Bad Homburg, Germany) and quantified.

Statistics. Student's t test was used to evaluate treatment differences in plasma or brain A40 and A42 levels and in A plaque load. When appropriate, data were transformed (log or square root) to normalize the results and to obtain homoscedasticity. Treatment differences in rating of goblet cell staining were tested with the Mann-Whitney U test. Calculations were done with the statistical software SigmaStat 2.0 for Windows (SPSS Inc., Chicago, IL). Results were presented as percentage of vehicle and as mean ± S.E.M.

	Results

Top Abstract Materials and Methods Results Discussion References

 
In Vitro Effects of CHF5074 on A Secretion. The effects of CHF5074 on A secretion were evaluated in H4swe, a human neuroglioma cell line expressing APPswe, mimicking the Tg2576 mouse model. CHF5074 concentrations ranging from 0.03 to 100 µM were evaluated. No fetal bovine serum was added to the medium to avoid the avid protein binding of CHF5074 (98.4 ± 0.4% with 10% serum; P. Petrillo, personal communication). At concentrations up to 30 µM, CHF5074 showed no or modest cytotoxicity as assessed by the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide assay (18% at 30 µM). However, at 100 µM a marked cytotoxicity was noted (49%), so that A levels were not considered at this drug concentration. At noncytotoxic concentrations, both A species were reduced by CHF5074, but with different sensitivities (Fig. 2). The estimated IC₅₀ values were 3.6 µM for A42 and 18.4 µM for A40. (R)-Flurbiprofen decreased A42 and A40 only at high concentrations, and formal IC₅₀ values were not calculated. At the maximal concentration of 300 µM, (R)-flurbiprofen reduced A42 levels to 24.2 ± 3.0% of vehicle and A40 levels to 75.6 ± 4.3% of vehicle. No significant cytotoxicity was detected with (R)-flurbiprofen at the concentrations tested (16% at 300 µM).

View larger version (10K): [in this window] [in a new window]   Fig. 2. CHF5074 preferentially inhibits A42 (A) versus A40 (B) in human neuroglioma cells (H4swe) expressing APPswe. A concentrations are expressed as percentage of control values (mean ± S.E.M., n = 3 for each concentration). The effects of high concentrations of (R)-flurbiprofen are also displayed. Estimated IC50 values of CHF5074 were 3.6 µM for A42 and 18.4 µM for A40. IC50 values for (R)-flurbiprofen were not computable.

View larger version (34K): [in this window] [in a new window]   Fig. 3. CHF5074 does not affect Notch intracellular processing at A-lowering concentrations in human embryonic kidney 293 cells (HEK293swe) expressing APPswe. At 5 µM no inhibition of Notch processing was present. At higher concentrations, a marked cytotoxicity was observed not allowing IC50 calculation.

View larger version (15K): [in this window] [in a new window]   Fig. 4. Chronic treatment with CHF5074 in the diet (375 ppm) for 17 weeks reduces brain but not plasma A levels in aged Tg2576 mice. Columns represent average A40 and A42 levels in brain (top, double-SDS plus formic acid sequentially extracted A, picomoles per gram ± S.E.M., n = 11–14 per column) and in plasma (picograms per milliliter ± S.E.M., n = 14 per column) of vehicle (open bars) or CHF5074 (closed bars)-treated animals. *, p < 0.05.

To evaluate the effects of CHF5074 on the peripheral A levels, we also measured plasma concentrations of A40 and A42 at the end of the 17-week treatment. No significant differences in the levels of both peptides were observed between CHF5074 treated and control mice (Fig. 4, bottom).

Effect of Chronic Treatment with CHF5074 on Brain Plaque Burden in Aged Tg2576 Mice. Paraffin-embedded sections were immunolabeled for A using the 6E10 antibody. A immunoreactivity in representative coronal sections of cortex and hippocampus of vehicle- and CHF5074-treated mice is shown in Fig. 5, A and B, respectively. Quantification of the immunoreactivity demonstrated significantly lower plaque area fraction in CHF5074-treated animals compared with controls in both cortex (Fig. 5C, –52.2 ± 5.6%; Student's t test, p = 0.0003) and hippocampus (Fig. 5D, –76.7 ± 6.4%; Student's t test, p = 0.004). Number of plaques was also significantly reduced by the CHF5074 treatment compared with controls in cortex (Fig. 5C, –48.9 ± 6.6%, Student's t test, p = 0.0004) and hippocampus (Fig. 5D, –66.2 ± 10.3%, Student's t test, p = 0.037). The mean size of the remaining plaques was not significantly different between the two treatment groups in either cortex (Fig. 5C, –15.4 ± 4.9%; Student's t test, p = 0.151) or hippocampus (Fig. 5D, –43.2 ± 14.1%; Student's t test, p = 0.100).

View larger version (54K): [in this window] [in a new window]   Fig. 5. Plaque burden is reduced in the brains of aged Tg2576 mice treated with CHF5074 in the diet (375 ppm) for 17 weeks. Immunostaining labeling of plaques with 6E10 antibody in representative coronal sections of cortex (A) and hippocampus (B) of mice treated with either vehicle or CHF5074. Quantification of immunostaining in cortex (C) and hippocampus (D). Note the significant reduction in the CHF5074-treated group (closed bars) compared with controls (open bars) in plaque area fraction and number of plaques of cortex (Student's t test, **, p < 0.01, n = 12–14) and hippocampus (Student's t test, **, p < 0.01 and *, p < 0.05, respectively, n = 8–12). Mean plaque areas of CHF5074- and vehicle-treated animals did not differ significantly in either cortex or hippocampus.

Effect of Chronic Treatment with CHF5074 on Brain Gliosis in Aged Tg2576 Mice. To determine whether CHF5074 treatment affected reactive astrocytosis associated to A deposition, immunostaining of GFAP with Z0334 antibody was performed in the CA1 region of hippocampus of the mice. GFAP immunoreactivity in representative sections of vehicle- and CHF5074-treated mice are shown in Fig. 6, top. Quantitation of immunostaining did not show significant differences between treatment groups in either the number of immunoreactive glial filaments or in total area occupied by the immunoreactive filaments (Fig. 6, bottom), although reduction in mean dimension of glial filaments in CHF5074-treated animals compared with controls approached statistical significance (–42.8 ± 6.3%; Student's t test, p = 0.057).

View larger version (61K): [in this window] [in a new window]   Fig. 6. Reactive gliosis in hippocampus of aged Tg2576 mice is not significantly reduced by CHF5074 treatment in the diet (375 ppm) for 17 weeks. Immunostaining of GFAP with Z0334 antibody in representative sections of the CA1 region of hippocampus of mice treated with either vehicle or CHF5074. Graph represents quantification of immunostaining labeling of vehicle-treated (open bars) and CHF5074-treated (closed bars) animals. There were no significant differences between treatment groups.

View larger version (164K): [in this window] [in a new window]   Fig. 7. Chronic treatment with CHF5074 in the diet (375 ppm) for 17 weeks does not induce abnormal histological changes main peripheral organs of aged Tg2576 mice. Representative sections of liver (A), kidneys (B), and spleen (C) (200x magnification) from one animal treated with vehicle (left) and one treated with CHF5074 (right).

View larger version (152K): [in this window] [in a new window]   Fig. 8. Chronic treatment with CHF5074 in the diet (375 ppm) for 17 weeks does not induce abnormal changes in ileum of aged Tg2576 mice. Representative sections of ileum tissues stained with Alcian Blue (200x magnification) from an animal treated with vehicle (A, staining score 3) and one treated with CHF5074 (B, staining score 3). Semiquantitative evaluation of goblet cells demonstrated that treatment with CHF5074 did not induce pathological changes in the ileum compared with the vehicle-treated group.

CHF5074 Plasma and Brain Levels after Chronic Treatment in Aged Tg2575 Mice. Based on diet consumption, the estimated ingested dose of CHF5074 was 60.8 ± 1.7 mg/kg/day. At the end of 17-week treatment, mean drug levels were 228.1 ± 10.1 µM in plasma and 6.4 ± 0.4 µMin the brain, with a mean brain-to-plasma ratio of 3.0 ± 0.3%.

	Discussion

Top Abstract Materials and Methods Results Discussion References

 
Different studies have shown that a subset of NSAIDs acts in vitro as -secretase modulators, i.e., they differentially inhibit the production of A42 and A40. The ability of these NSAIDs to lower brain A levels and plaque deposition in vivo has been reported for ibuprofen (Lim et al., 2000, 2001; Yan et al., 2003), indomethacin (Sung et al., 2004) and flurbiprofen derivatives (Jantzen et al., 2002; van Groen et al., 2005; Wilcock et al., 2007). Our data represent the first demonstration that chronic administration of a -secretase modulator devoid of anti-COX activity can significantly reduce the deposition of A in the brain. We have demonstrated a marked decrease in both the number and total area occupied by amyloid deposits in the cortex and hippocampus of CHF5074-treated mice compared with their vehicle-treated controls. The average size of the remaining plaques was not significantly affected by the CHF5074 treatment. This suggests that CHF5074 is effective in inhibiting the initiation of the formation of plaques but less effective in inhibiting the growth of the plaques. Similar results were reported after chronic treatment with ibuprofen in the diet (375 ppm for 4 months; Yan et al., 2003) and indomethacin in the drinking water (10 mg/l for 8 months; Sung et al., 2004) in Tg2576 mice of comparable age (15 months) at sacrifice. Another study in 10-month-old Tg2576 mice receiving ibuprofen in the diet for 6 months (375 ppm) produced also similar results (Lim et al., 2000). Comparable effects were also recently described in 15-month-old Tg2576 mice after chronic treatment with the -secretase inhibitor MRK-560 (3 mg/kg/day for 3 months; Best et al., 2007).

It has been shown that sequential extraction of brain homogenates using SDS and FA solubilizes most of the total amyloid pool from brains of Tg2576 mice (Kawarabayashi et al., 2001), except for some plaque core and vascular amyloid. At 15 months of age, the SDS-extractable A represents approximately 10% of the A pool extracted by FA (Kawarabayashi et al., 2001). Because -secretase modulators are thought to mainly affect SDS-extractable A pools, i.e., the newly formed A (Yan et al., 2003; Dvir et al., 2006), a double SDS extraction was performed in an attempt to maximize this A fraction. Indeed, the double SDS-extracted A in our study represented 46 to 47% of the total extracted A. The lowering effects of the CHF5074 treatment on the double-SDS fraction (–43% for A40 and –38% for A42) was similar to that found for the FA fraction (–57% for A40, –49% for A42). Overall, the CHF5074-induced decrease of total extracted A40 (–49%) and A42 (–44%) in the brain hemispheres agreed well with the decrease in plaque number (44–66%) and total plaque area (52–77%) in cortex and hippocampus assessed by immunostaining, suggesting that these biochemical measures are an accurate reflection of overall amyloid load. On the contrary, we did not observe a significant reduction in plasma A42 or A40 levels in CHF5074-treated animals. This is in contrast with what was found in a previous study in young plaque-free Tg2576 mice in which a significant reduction in A levels was observed in plasma but not in brain after a 4-day treatment (Imbimbo et al., 2007). In that study, the doses of CHF5074 were higher (100 and 300 mg/kg/day) than in the present study (61 mg/kg/day), and they were given by oral gavage. In addition, brain A was extracted with only formic acid. It could be that the effects of CHF5074 on central and peripheral A vary depending from the age of the animal, the dose, and the duration of the treatment.

The mechanism(s) through which chronic treatment with CHF5074 ameliorates amyloid pathology remains to be elucidated. In the present study, CHF5074 concentrations reached in the brain (6.4 ± 0.4 µM) were enough to efficiently inhibit A42 secretion (cell-based IC₅₀ = 3.6 µM). These brain concentrations are not higher than those attained in young transgenic Tg2576 mice after short-term treatment (10.2 ± 3.7 µM, after 100 mg/kg/day for 4 days) where we failed to demonstrate a decrease in brain A levels (Imbimbo et al., 2007). This is in line with previous reports indicating that short-term administration (3–8 days) of A-lowering NSAIDs in young Tg2576 transgenic mice does not attain significant effects on brain A levels (Lanz et al., 2005; Peretto et al., 2005; Stock et al., 2006). Alternatively, long-term treatments (3–8 months) with ibuprofen (Lim et al., 2000, 2001; Yan et al., 2003) indomethacin (Sung et al., 2004), or flurbiprofen derivatives (Jantzen et al., 2002; van Groen et al., 2005; Wilcock et al., 2007) have shown a significant reduction in brain A pathology in transgenic mice. It is possible that -secretase modulators do not act centrally but rather peripherally by increasing A42 clearance, and, in turn, by enhancing efflux of A42 from the brain. However, the lack of the significant decreasing effect of CHF5074 on plasma A42 does not support this hypothesis. It cannot be excluded that CHF5074 may decrease A deposition acting through other mechanisms such as activation of the peroxisome proliferator-activated receptor- (Camacho et al., 2004; Sastre et al., 2006) for which the compound displays a K_i value of approximately 10 µM (G. Villetti, personal communication).

Plaque formation and maturation are normally accompanied by inflammatory processes. GFAP immunostaining suggested a reduction of the extension of glial filaments of Tg2576 mice chronically treated with CHF5074. This preliminary finding may indicate a decrease in the activation of glia. More detailed immunohistochemistry work with morphological evaluation and quantification would be required to confirm this hypothesis, because there is no evidence in a reduction in number of glial filaments and their total area.

Our in vitro studies in H4swe cells confirmed previous studies showing that CHF5074 preferentially inhibits A42 versus A40 secretion (Imbimbo et al., 2007). However, the estimated in vitro potency of CHF5074 on A42 secretion was considerably higher than in previous studies (3.6 versus 40.0 µM). This 10-fold difference is probably due to the absence of fetal bovine serum in medium of the present experiments, which avoided avid binding of CHF5074 to proteins contained in fetal bovine serum. We do not know which of the two IC₅₀ values are the most relevant in vivo. The 5-fold preferential inhibitory activity of CHF5074 on A42 observed in vitro was not observed in vivo. In Tg2576 mice of 12 to 15 months of age, diffuse plaques are mainly formed of A42 (Kawarabayashi et al., 2001), meaning that more A42 than A40 is accumulated in the brains of these animals. This may counterbalance the higher potency of CHF5074 in preferentially inhibiting A42 secretion. Alternatively, it could simply be that in vitro selectivity of CHF5074 is not high enough to translate in an in vivo measurable effect.

CHF5074 was very well tolerated in young Tg2576 mice when administered in the diet at 375 ppm for 17 weeks (estimated assumed dose of 61 mg/kg/day). No deaths occurred during the 17-week treatment period. Body weight and body weight gain over time were very similar to those of the vehicle-treated group. At week 17, macroscopic and histological examinations of potential peripheral target organs did not show significant abnormalities. In the ileum, there were no differences in goblet cell numbers and distribution between the vehicle-dosed animals and the animals receiving CHF5074. The spleen of the CHF5074-treated animals did not show histological abnormalities. Finally, histological evaluation of other portions of the gastrointestinal tract revealed no abnormalities. Overall, our data demonstrate that chronic treatment with CHF5074 can significantly reduce the induction of amyloid deposits in the brains of Tg2576 mice without causing histopathological changes in peripheral organs that would be associated with inhibition of processing of alternative substrates by this enzyme complex. Indeed, different reports have shown that the subset of NSAIDs acting as -secretase modulators can distinguish between the proteolytic activities on APP and Notch (Weggen et al., 2001, 2003b). This characteristic differentiates -secretase modulators from traditional -secretase inhibitors that in addition to APP may affect processing of alternative substrates for -secretase, particularly the Notch family of receptors. Genetic deletion of the Notch pathway in mice results in defects in the gastrointestinal tract with a phenotype similar to that observed using a -secretase inhibitor (van Es et al., 2005). Intestinal goblet cell metaplasia and cell population changes in the ileum have been observed with several -secretase inhibitors (Searfoss et al., 2003; Milano et al., 2004; Wong et al., 2004). In addition, -secretase inhibitors have been associated to alteration of lymphopoiesis (Wong et al., 2004) and atrophy of the thymus (Hadland et al., 2001). Toxicity of the -secretase inhibitors may be linked to the specific chemical structure, since it has been shown that MRK-560, a potent APP and Notch cleavage inhibitor (IC₅₀ values = 4.32 and 3.44 nM, respectively), administered for 3 months to aged Tg2576 mice significantly reduced brain A pathology without causing histopathological changes in the ileum, spleen, or thymus (Best et al., 2007). Our present studies in HEK293swe cells indicated that CHF5074 concentrations inhibiting APP processing (5 µM) do not affect Notch processing. Previous studies in H4swe cells have shown that CHF5074, at the concentration of 100 µM, did not inhibit the expression of 20 Notch intracellular domain-responsive genes (Imbimbo et al., 2007). The lack of toxic effects on gastrointestinal tissues and on spleen observed in this study seems to confirm the good selectivity on CHF5074 for APP cleavage. Further formal chronic toxicological studies are needed to confirm these preliminary findings.

In conclusion, this study shows that 4-month treatment with CHF5074 in the diet (61 mg/kg/day) seems to be safe and well tolerated in aged Tg2576 transgenic mice. CHF5074 treatment markedly reduced total brain A40 and A42 levels and plaque burden in cortex and hippocampus, both in terms of plaque area fraction and number of plaques. CHF5074 is therefore a novel -secretase modulator that has the potential to be a safe and promising therapeutic agent for AD treatment.

	Footnotes

 
The work was sponsored by Chiesi Farmaceutici, Parma, Italy. A part of this study was presented at the 8th International Conference on Alzheimer's and Parkinson's Diseases; 2007 March 14–18; Salzburg, Austria.

Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.

doi:10.1124/jpet.107.129007.

ABBREVIATIONS: AD, Alzheimer's disease; A, -amyloid peptide; APP, amyloid precursor protein; NSAID, nonsteroidal anti-inflammatory drug; COX, cyclooxygenase; CHF5074, 1-(3',4'-dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid; APPswe, Swedish mutated form of APP; H4swe, human neuroglioma cell line expressing APPswe; HEK293swe, human embryonic kidney 293 cells expressing APPswe; FA, formic acid; ELISA, enzyme-linked immunosorbent assay; GFAP, glial fibrillar acidic protein; MRK-560, N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethane sulfonamide.

Address correspondence to: Dr. Bruno P. Imbimbo, Research & Development, Chiesi Farmaceutici, via Palermo 26/A, 43100 Parma, Italy. E-mail: b.imbimbo{at}chiesigroup.com

	References

Top Abstract Materials and Methods Results Discussion References

 

ADAPT Research Group: Lyketsos CG, Breitner JC, Green RC, Martin BK, Meinert C, Piantadosi S, Sabbagh M (2007) Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology 68: 1800–1808.[Abstract/Free Full Text]

Aisen PS, Davis KL, Berg JD, Schafer K, Campbell K, Thomas RG, Weiner MF, Farlow MR, Sano M, Grundman M, et al. (2000) A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology 54: 588–593.[Abstract/Free Full Text]

Aisen P, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, and Thal LJ (2003) Effects of rofecoxib or naproxen vs. placebo on Alzheimer disease progression. J Am Med Assoc 289: 2819–2826.[Abstract/Free Full Text]

Beher D, Clarke EE, Wrigley JD, Martin AC, Nadin A, Churcher I, and Shearman MS (2004) Selected non-steroidal anti-inflammatory drugs and their derivatives target -secretase at a novel site. Evidence for an allosteric mechanism. J Biol Chem 279: 43419–43426.[Abstract/Free Full Text]

Best JD, Smith DW, Reilly MA, O'Donnell R, Lewis HD, Ellis S, Wilkie N, Rosahl TW, Laroque P, Boussiquet-Leroux C, et al. (2007) The novel -secretase inhibitor MRK-560 reduces amyloid plaque deposition without evidence of Notch-related pathology in the Tg2576 mouse. J Pharmacol Exp Ther 320: 552–558.[Abstract/Free Full Text]

Camacho IE, Serneels L, Spittaels K, Merchiers P, Dominguez D, De Strooper B (2004) Peroxisome-proliferator-activated receptor induces a clearance mechanism for the amyloid- peptide. J Neurosci 24: 10908–10917.[Abstract/Free Full Text]

Dvir E, Friedman JE, Lee JY, Koh JY, Younis F, Raz S, Shapiro I, Hoffman A, Dahan A, Rosenberg G, et al. (2006) A novel phospholipid derivative of indomethacin, DP-155 [mixture of 1-steroyl and 1-palmitoyl-2-{4-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indolyl acetamido]butanoyl}-sn-glycero-3-phosophatidyl choline], shows superior safety and similar efficacy in reducing brain amyloid beta in an Alzheimer's disease model. J Pharmacol Exp Ther 318: 1248–1256.[Abstract/Free Full Text]

Eriksen JL, Sagi SA, Smith TE, Weggen S, Das P, McLendon DC, Ozols VV, Jessing KW, Zavitz KH, Koo EH, et al. (2003) NSAIDs and enantiomers of flurbiprofen target -secretase and lower A42 in vivo. J Clin Invest 112: 440–449.[CrossRef][Medline]

Facchinetti F, Fasolato C, Del Giudice E, Burgo A, Furegato S, Fusco M, Basso E, Seraglia R, D'Arrigo A, and Leon A (2006) Nimodipine selectively stimulates -amyloid1-42 secretion by a mechanism independent of calcium influx blockage. Neurobiol Aging 27: 218–227.[CrossRef][Medline]

Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, Krafft GA, and Klein WL (2003) Alzheimer's disease-affected brain: presence of oligomeric A ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci USA 100: 10417–10422.[Abstract/Free Full Text]

Hadland BK, Manley NR, Su D, Longmore GD, Moore CL, Wolfe MS, Schroeter EH, and Kopan R (2001) -Secretase inhibitors repress thymocyte development. Proc Natl Acad SciUSA 98: 7487–7491.[Abstract/Free Full Text]

Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, and Cole G (1996) Correlative memory deficits, A elevation, and amyloid plaques in transgenic mice. Science 274: 99–102.[Abstract/Free Full Text]

Imbimbo BP, Del Giudice E, Cenacchi V, Volta R, Villetti V, Facchinetti F, Riccardi B, Puccini P, Moretto N, Grassi F, et al. (2007) In vitro and in vivo profiling of CHF5022 and CHF5074, two -amyloid_1-42 lowering agents. Pharmacol Res 55: 318–328.[CrossRef][Medline]

Jantzen PT, Connor KE, DiCarlo G, Wenk GL, Wallace JL, Rojiani AM, Coppola D, Morgan D, and Gordon MN (2002) Microglial activation and -amyloid deposit reduction caused by a nitric-oxide-releasing non-steroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci 22: 2246–2254.[Abstract/Free Full Text]

Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, and Younkin SG (2001) Age-dependent changes in brain, CSF, and plasma amyloid () protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci 21: 372–381.[Abstract/Free Full Text]

Lanz TA, Fici GJ, and Merchant KM (2005) Lack of specific amyloid-_1–42 suppression by nonsteroidal anti-inflammatory drugs in young, plaque-free Tg2576 mice and in guinea pig neuronal cultures. J Pharmacol Exp Ther 312: 399–406.[Abstract/Free Full Text]

Lim GP, Yang F, Chu T, Chen P, Beech W, Teter B, Tran T, Ubeda O, Ashe KH, Frautschy SA, et al. (2000) Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci 20: 5709–5714.[Abstract/Free Full Text]

Lim GP, Yang F, Chu T, Gahtan E, Ubeda O, Beech W, Overmier JB, Hsiao-Ashec K, Frautschy SA, and Cole GM (2001) Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol Aging 22: 983–991.[CrossRef][Medline]

Lleó A, Berezovska O, Herl L, Raju S, Deng A, Bacskai BJ, Frosch MP, Irizarry M, and Hyman BT (2004) Nonsteroidal anti-inflammatory drugs lower A42 and change presenilin 1 conformation. Nat Med 10: 1065–1066.[CrossRef][Medline]

Milano J, McKay J, Dagenais C, Foster-Brown L, Pognan F, Gadient R, Jacobs RT, Zacco A, Greenberg B, and Ciaccio PJ (2004) Modulation of notch processing by -secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol Sci 82: 341–358.[Abstract/Free Full Text]

Morihara T, Chu T, Ubeda O, Beech W, and Cole GM (2002) Selective inhibition of A42 production by NSAID R-enantiomers. J Neurochem 83: 1009–1012.[CrossRef][Medline]

Peretto I, Radaelli S, Parini C, Zandi M, Raveglia LF, Dondio G, Fontanella L, Misiano P, Bigogno C, Rizzi A, et al. (2005) Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of -amyloid_1-42 secretion. J Med Chem 48: 5705–5720.[CrossRef][Medline]

Reines SA, Block GA, Morris JC, Liu G, Nessly ML, Lines CR, Norman BA, Baranak CC; Rofecoxib Protocol 091 Study Group (2004) Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 62: 66–71.[Abstract/Free Full Text]

Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW, Zalinski J, Cofield M, Mansukhani L, Willson P, et al. (1993) Clinical trial of indomethacin in Alzheimer's disease. Neurology 43: 1609–1611.[Abstract/Free Full Text]

Sainati SM, Ingram DM, Talwalker S, and Geis G (2000) Results of a double-blind, randomized, placebo-controlled study of celecoxib in the treatment of progression of Alzheimer's disease, in 6th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5–8; Stockholm, Sweden. Abstract Book, p 180.

Sastre M, Dewachter I, Rossner S, Bogdanovic N, Rosen E, Borghgraef P, Evert BO, Dumitrescu-Ozimek L, Thal DR, Landreth G, et al. (2006) Nonsteroidal antiinflammatory drug repress -secretase gene promoter activity by the activation of PPAR. Proc Natl Acad SciUSA 103: 443–448.[Abstract/Free Full Text]

Searfoss GH, Jordan WH, Calligaro DO, Galbreath EJ, Schirtzinger LM, Berridge BR, Gao H, Higgins MA, May PC, and Ryan TP (2003) Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional -secretase inhibitor. J Biol Chem 278: 46107–46116.[Abstract/Free Full Text]

Stock N, Munoz B, Wrigley JD, Shearman MS, Beher D, Peachey J, Williamson TL, Bain G, Chen W, Jiang X, et al. (2006) The geminal dimethyl analogue of flurbiprofen as a novel A42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg Med Chem Lett 16: 2219–2223.[CrossRef][Medline]

Sung S, Yang H, Uryu K, Lee EB, Zhao L, Shineman D, Trojanowski JQ, Lee VM, and Praticò D (2004) Modulation of NF-B activity by indomethacin influences A levels but not APP metabolism in a model of Alzheimer disease. Am J Pathol 165: 2197–2206.[Abstract/Free Full Text]

Szekely CA, Thorne JE, Zandi PP, Ek M, Messias E, Breitner JC, and Goodman SN (2004) Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology 23: 159–169.[CrossRef][Medline]

Takahashi Y, Hayashi I, Tominari Y, Rikimaru K, Morohashi Y, Kan T, Natsugari H, Fukuyama T, Tomita T, and Iwatsubo T (2003) Sulindac sulfide is a noncompetitive -secretase inhibitor that preferentially reduces A42 generation. J Biol Chem 278: 18664–18670.[Abstract/Free Full Text]

Thal LJ, Ferris SH, Kirby L, Block GA, Lines CR, Yuen E, Assaid C, Nessly ML, Norman BA, Baranak CC, et al. (2005) Rofecoxib Protocol 078 study group. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 30: 1204–1215.[CrossRef][Medline]

van Es JH, van Gijn ME, Riccio O, van den Born M, Vooijs M, Begthel H, Cozijnsen M, Robine S, Winton DJ, Radtke F, et al. (2005) Notch/-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 435: 959–963.[CrossRef][Medline]

Van Gool WA, Weinstein HC, Scheltens P, Walstra GJ, and Scheltens PK (2001) Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study. Lancet 358: 455–460.[CrossRef][Medline]

van Groen T and Kadish I (2005) Transgenic AD model mice, effects of potential anti-AD treatments on inflammation and pathology. Brain Res Brain Res Rev 48: 370–378.[CrossRef][Medline]

Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, et al. (2001) A subset of NSAIDs lower amyloidogenic A42 independently of cyclooxygenase activity. Nature 414: 212–216.[CrossRef][Medline]

Weggen S, Eriksen JL, Sagi SA, Pietrzik CU, Golde TE, and Koo EH (2003a) A42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain. J Biol Chem 278: 30748–30754.[Abstract/Free Full Text]

Weggen S, Eriksen JL, Sagi SA, Pietrzik CU, Ozols V, Fauq A, Golde TE, and Koo EH (2003b) Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid 42 production by direct modulation of -secretase activity. J Biol Chem 278: 31831–31837.[Abstract/Free Full Text]

Wilcock DM, Jantzen PT, Li Q, Morgan D, and Gordon MN (2007) Amyloid- vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. Neuroscience 144: 950–960.[CrossRef][Medline]

Wong GT, Manfra D, Poulet FM, Zhang Q, Josien H, Bara T, Engstrom L, Pinzon-Ortiz MC, Fine JS, Lee HJ, et al. (2004) Chronic treatment with the -secretase inhibitor LY-411,575 inhibits A production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 279: 12876–12882.[Abstract/Free Full Text]

Yan Q, Zhang J, Liu H, Babu-Khan S, Vassar R, Biere AL, Citron M, and Landreth G (2003) Anti-inflammatory drug therapy alters -amyloid processing and deposition in an animal model of Alzheimer's disease. J Neurosci 23: 7504–7509.[Abstract/Free Full Text]

This article has been cited by other articles:

				E. Czirr, B. A. Cottrell, S. Leuchtenberger, T. Kukar, T. B. Ladd, H. Esselmann, S. Paul, R. Schubenel, J. W. Torpey, C. U. Pietrzik, et al. Independent Generation of A{beta}42 and A{beta}38 Peptide Species by {gamma}-Secretase J. Biol. Chem., June 20, 2008; 283(25): 17049 - 17054. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: jpet.107.129007v1 323/3/822    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Imbimbo, B. P. Articles by Leon, A. Search for Related Content PubMed PubMed Citation Articles by Imbimbo, B. P. Articles by Leon, A.